Compound library/CJC-1295 / Ipamorelin

CJC-1295 / Ipamorelin

Two different compounds, almost always sold stacked together. CJC-1295 is a growth hormone releasing hormone analogue; ipamorelin is a selective ghrelin receptor agonist. Both raise growth hormone. Neither is approved, and neither has trials supporting the body composition and anti-ageing claims made for them.

Last reviewed September 2026 ยท No commercial relationship with any manufacturer

How it works

The pairing is deliberate. CJC-1295 mimics growth hormone releasing hormone and increases the size of GH pulses; ipamorelin acts on the ghrelin receptor and increases their frequency. Used together they raise GH and downstream IGF-1 more than either does alone.

That the pair raises GH and IGF-1 is not in dispute. What is in dispute is whether raising them in an adult with normal GH produces any of the outcomes being sold: fat loss, muscle gain, better sleep, slower ageing. No trial has shown that.

What the evidence shows

The published work is small early-phase pharmacology establishing that these compounds do raise GH and IGF-1. There are no controlled trials of the clinical outcomes they are marketed for. A biomarker moving is not an outcome.

Typical dosing

No approved dose for either compound. Clinic protocols vary widely and are not derived from outcome trials.

Reported side effects

Effects reported with GH elevation generally include water retention, joint pain, carpal tunnel symptoms and reduced insulin sensitivity. Rates for this specific combination have not been established in controlled study.

Labelled warnings and contraindications

  • Sustained elevation of GH and IGF-1 is not a benign intervention. Insulin resistance, oedema and arthralgia are the recognised effects of raising GH in adults who do not need it.
  • IGF-1 is a growth signal, which is the basis of the standing caution about elevating it in anyone with an undiagnosed malignancy. Not demonstrated harm, but the reason endocrinology treats GH as a replacement therapy rather than an enhancement.
  • Both compounds appear on FDA's Category 2 bulk drug substances list, closing the compounding route.
  • Prohibited by the World Anti-Doping Agency.

Legal status and sourcing

Neither compound is FDA approved. Both were placed in FDA's Category 2 bulk substances review, which means compounding pharmacies cannot lawfully prepare them.

Growth hormone itself is separately restricted in the United States: distributing it for anything other than a specific approved indication is a criminal offence. Secretagogues sit adjacent to that restriction rather than outside it.

What it costs

Clinic pricing for growth hormone secretagogue protocols is usually bundled into a wider wellness programme rather than sold on its own, which makes a like-for-like monthly figure close to meaningless. We are not publishing one, because any number we gave would be wrong for most people who asked.

How confident anyone can be

Low. The pharmacology is real and the clinical claims are not evidenced.

This is the category where the gap between clinic marketing and published evidence is widest, and where the legal footing is least stable.

Related reading

Educational only. Nothing here is medical advice, and nothing here substitutes for a conversation with a licensed clinician who knows your history. Dosing, side effects and outcomes vary between people.